Clinical Trials Logo

Eczema clinical trials

View clinical trials related to Eczema.

Filter by:

NCT ID: NCT05642208 Recruiting - Atopic Dermatitis Clinical Trials

Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

MADULO
Start date: March 8, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to compare a step-down strategy of spacing dupilumab injections with a standard maintenance treatment in adolescents and adults with controlled Atopic dermatitis (AD) for at least six months. The impact of dosage reduction strategies will be assessed with an innovative primary endpoint: the area under the curve of the weekly ADCT assessment.

NCT ID: NCT05613062 Recruiting - Atopic Dermatitis Clinical Trials

Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children

Start date: April 11, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The study aims to evaluate the clinical efficacy of Chinese medicine (CM) for the treatment of subacute and chronic Atopic Dermatitis (AD) patients when compared to the placebo control by examining the clinical symptoms.

NCT ID: NCT05602207 Recruiting - Atopic Dermatitis Clinical Trials

Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

Start date: November 25, 2022
Phase: Phase 4
Study type: Interventional

This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.

NCT ID: NCT05579925 Recruiting - Atopic Dermatitis Clinical Trials

A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

Start date: October 7, 2022
Phase: Phase 2
Study type: Interventional

This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.

NCT ID: NCT05578482 Recruiting - Atopic Dermatitis Clinical Trials

Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis

Start date: October 24, 2022
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to compare and evaluate in patients with atopic dermatitis. The main questions it aims to answer are: - Does the addition of systemic dicloxacillin to TCS treatment result in a more rapid and deeper treatment response? - Does the addition of systemic dicloxacillin to TCS treatment affect the skin microbiome, the skin barrier and immune response during improvement of AD? - Does topical application of S. aureus or SEB increase the severity and rapidity of a flare? Participants will meet for two different phases: - Phase one will be at randomized controlled trial where patients are randomized to either systemic dicloxacillin + mometasone furoate or placebo + mometasone furoate. - Phase II: Patients will meet for five visits to receive different solutions on the skin including autologous s. aureus and staphylococcal enterotoxin B.

NCT ID: NCT05575882 Recruiting - Atopic Dermatitis Clinical Trials

Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream Intended for Very Dry, Irritated to Atopic Sensitive Skin.

Start date: November 3, 2022
Phase: N/A
Study type: Interventional

Multicentric, double blind, randomized, comparative study with two parallel group: study group vs placebo group. 5 visits: inclusion visit [day (D) 0] and 4 follow-up visits (D30, D60, D90, and D120).

NCT ID: NCT05566262 Recruiting - Atopic Dermatitis Clinical Trials

Bodewell Products for the Treatment of Atopic Dermatitis

Start date: November 1, 2023
Phase: Phase 4
Study type: Interventional

This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products

NCT ID: NCT05559359 Recruiting - Atopic Dermatitis Clinical Trials

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

ADorable-1
Start date: October 18, 2022
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).

NCT ID: NCT05527964 Recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic

Start date: December 31, 2022
Phase:
Study type: Observational [Patient Registry]

Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: - Change in disease activity after 16 and 24 weeks - Change in subject and family quality of life after 16 and 24 weeks - Change in sleep quality after 16 and 24 weeks - Change in anxiety after 16 and 24 weeks - Change in depression after 16 and 24 weeks - Safety and tolerability

NCT ID: NCT05526222 Recruiting - Atopic Dermatitis Clinical Trials

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

Start date: July 14, 2022
Phase: Phase 3
Study type: Interventional

A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis